Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
US stocks were expected to head in different directions on Thursday morning, as oil prices retreat but tech earnings overnight disappointed investors. Dow Jones futures were called 0.8% higher, but the S&P 500 was off 0.4% and Nasdaq futures were down 1.3%. The latter pair were...
Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai
The outlook lift comes on expectations of stronger momentum in the group’s life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million